Point72 DIFC Ltd Buys New Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Point72 DIFC Ltd purchased a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 12,900 shares of the company’s stock, valued at approximately $334,000.

Several other institutional investors have also bought and sold shares of the business. SG Americas Securities LLC purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at about $112,000. WINTON GROUP Ltd purchased a new stake in Dianthus Therapeutics during the second quarter valued at approximately $265,000. Virtu Financial LLC bought a new stake in shares of Dianthus Therapeutics in the 1st quarter valued at approximately $390,000. Hussman Strategic Advisors Inc. purchased a new position in shares of Dianthus Therapeutics in the 1st quarter worth approximately $630,000. Finally, American Century Companies Inc. increased its position in shares of Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after purchasing an additional 8,473 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Up 1.2 %

Shares of NASDAQ:DNTH opened at $27.02 on Friday. The business’s 50 day moving average is $27.90 and its 200 day moving average is $26.20. The stock has a market cap of $793.04 million, a P/E ratio of -4.63 and a beta of 1.85. Dianthus Therapeutics, Inc. has a 52-week low of $6.58 and a 52-week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The firm had revenue of $1.86 million for the quarter, compared to the consensus estimate of $0.63 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. On average, sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.32 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on DNTH. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday. Lifesci Capital upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Robert W. Baird began coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 price objective for the company. Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Finally, Wedbush reduced their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $44.71.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.